Supplier to Physiotherapists, General Public, the NHS & Armed Forces

Infections Related to Biologics An Issue of Infectious Disease Clinics of North America

Not rated yet
0
In collaboration with Consulting Editor Dr. Helen Boucher, Drs. Aruna Subramanian and Dora Yuk-Wai Ho have created an extremely timely and relevant issue for infectious disease physcians, as the field of biologics is exploding. These new agents are being used in rheumatologic diseases, hematologic malignancies, solid tumors, and other conditions; there is a lack of guidance in the literature on how to address their infectious risks.  The first 9 articles explain the mechanisms of action of the biologic agents and the infectious disease risks associated with their immune system targets.  The last few articles go into more depth on the viral, fungal, and mycobacterial infections that are potentiated by biologics, and discuss recommended prophylaxis and preventative strategies, including vaccinations. Specifically, articles are devoted to the following: TNF inhibitors; Agents targeting B cells; Agents targeting T cell activation; Direct T cell inhibition and agents targeting T cell migration and chemotaxis; IL-1 and IL-6 and other interleukin and IgE inhibition; Check-point inhibitors; Tyrosine kinase inhibitors for heme malignancies; EGFR inhibitors and other Tyrosine kinase inhibitors for solid tumors; Targeting JAK-STAT signaling and complement pathway for inflammatory diseases; Viral infections Potentiated by Biologics (and Prophylaxis); Endemic Fungal Infections Potentiated by Biologics (and prophylaxis); Mycobacterial Infections Potentiated by Biologics; and Vaccinations for patients on biologics. Readers will come away with the clinical overviews of these topics to improve prevention and management of patients treated with biologics.
73   – Reward points
Availability: MD - Manufactured on demand
    • 10% off
    £81.99, save £8.20
  • £73.79
Qty:  
  • Shipping info

    Our publishing partner, Elsevier, maintains a flat fee for shipping. Books are delivered in the UK via DHL and will require a signature upon delivery.

    The standard delivery time within the UK is 2 working days from the date of invoice.

    Manufactured on demand titles take an extra 3-5 working days.

    At this time we only ship Elsevier book orders to addresses within the UK.

    Brexit: We have been informed that some couriers are now charging additional fees for importing from the UK into the EU. The customer is responsible for the payment of any import duties that are in addition to the shipping costs already charged.

  • Payment methods

    logos-payments-tab_1.png

In collaboration with Consulting Editor Dr. Helen Boucher, Drs. Aruna Subramanian and Dora Yuk-Wai Ho have created an extremely timely and relevant issue for infectious disease physcians, as the field of biologics is exploding. These new agents are being used in rheumatologic diseases, hematologic malignancies, solid tumors, and other conditions; there is a lack of guidance in the literature on how to address their infectious risks.  The first 9 articles explain the mechanisms of action of the biologic agents and the infectious disease risks associated with their immune system targets.  The last few articles go into more depth on the viral, fungal, and mycobacterial infections that are potentiated by biologics, and discuss recommended prophylaxis and preventative strategies, including vaccinations. Specifically, articles are devoted to the following: TNF inhibitors; Agents targeting B cells; Agents targeting T cell activation; Direct T cell inhibition and agents targeting T cell migration and chemotaxis; IL-1 and IL-6 and other interleukin and IgE inhibition; Check-point inhibitors; Tyrosine kinase inhibitors for heme malignancies; EGFR inhibitors and other Tyrosine kinase inhibitors for solid tumors; Targeting JAK-STAT signaling and complement pathway for inflammatory diseases; Viral infections Potentiated by Biologics (and Prophylaxis); Endemic Fungal Infections Potentiated by Biologics (and prophylaxis); Mycobacterial Infections Potentiated by Biologics; and Vaccinations for patients on biologics. Readers will come away with the clinical overviews of these topics to improve prevention and management of patients treated with biologics.
    • SKU
      9780323733205
    • UPC/ISBN
      9780323733205
    • Stock Last Checked
      Nov 30, 2021
  • Manufacturer
    Elsevier
  • Publication Date
    Jun 4, 2020
Customer reviews
There are no comments yet. Be the first to leave a comment
Please sign in to add review

Your Elsevier book orders are actioned within 48hrs during the working week. If any one item in your purchase is delayed we will send you what is in stock and will send on the remainder as soon as it arrives. This is provided at no additional shipping cost to you. Stock availability levels are updated on a daily basis.  We ship directly from a UK warehouse.

Shipping Costs

We currently maintain a flat fee structure for shipping book titles from Elsevier. Buy as many Elsevier titles as you like the we will still charge you the same single item shipping fee.

Overview Delivery Methods

Books are delivered in the UK via DHL and will require a signature upon delivery.

Deliveries within the UK

  • The standard delivery time within the UK is 2 working days from the date of invoice.
  • Print on demand titles take 3-5 working days.

Where is my order? Order Tracking

To find out more information about your order, select from the relevant options below:

Deliveries to the UK and UK shippers

Your order should be delivered to you/your shipper within 2-3 working days.

To track any deliveries using DPD, click here.

If your order is for a print on demand title, your delivery time will be longer, please allow an extra 3-5 working days.

We accept the following payment methods:

Elsevier maintains a standard returns policy